Nicorette Invisi Transdermal Patch

Nicorette Invisi Transdermal Patch

nicotine

Manufacturer:

Johnson & Johnson

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Nicotine
Indications/Uses
Tobacco dependence by relieving nicotine craving & w/drawal symptoms facilitating smoking cessation in smokers motivated to quit.
Dosage/Direction for Use
Heavy smoker One 25-mg patch/16 hr daily for 1st 8 wk, then one 15-mg patch/16 hr daily for the next 2 wk & one 10-mg patch/16 hr daily for the final 2 wk. Light smoker One 15-mg patch/16 hr daily for 1st 8 wk then one 10-mg patch/16 hr daily for the final 4 wk.
Special Precautions
Serious CV event, hospitalization for CV complaint; previous stroke, MI, unstable angina, cardiac arrhythmia, coronary artery bypass graft & angioplasty; uncontrolled HTN. Active duodenal & gastric ulcers. Uncontrolled hyperthyroidism or phaeochromocytoma. DM. Remove patch prior to MRI procedures. Treatment beyond 6 mth. Severe/moderate hepatic impairment, severe renal impairment. Pregnancy & lactation. Childn <18 yr.
Adverse Reactions
Nausea, vomiting; fatigue; hypersensitivity; headache; paraesthesia; pruritus.
Drug Interactions
Increased plasma levels of theophylline, tacrine, clozapine, ropinirole. Affected metabolism of imipramine, olanzapine, clomipramine, fluvoxamine; flecainide & pentazocine.
ATC Classification
N07BA01 - nicotine ; Belongs to the class of drugs used in the management of nicotine dependence.
Presentation/Packing
Form
Nicorette Invisi Transdermal Patch 15 mg
Packing/Price
7 × 1's
Form
Nicorette Invisi Transdermal Patch 10 mg
Packing/Price
7 × 1's
Form
Nicorette Invisi Transdermal Patch 25 mg
Packing/Price
7 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in